Fairvalue-Calculator Fairvalue-Calculator
EN DE

Urteste S.A (URT) Fair Value & Analysis

Healthcare · PL · Market cap 66.1M PLN

Price42.90 PLN
Fair Value73.51 PLN
Upside+71.4%
Quality95/100
Evidence: Low Range 55.13 PLN – 91.88 PLN

Fair value as of: Jun 24, 2026

Analysis

Urteste S.A (URT) currently trades at 42.90 PLN, while our model-based Fair Value estimate is 73.51 PLN — implying the stock looks roughly 71.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Urteste S.A (URT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 73.51 PLN versus a price of 42.90 PLN — about +71% (undervalued). Model-based estimate, not financial advice.
What is the fair value of URT?
Our 21-model fair value for Urteste S.A is 73.51 PLN (as of Jun 24, 2026), built from audited fundamentals. The current price is 42.90 PLN.
What is the quality score of URT?
Urteste S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.